SCHEMBL4977889

SCHEMBL4977889

OCCc1ccc(O)c(Br)c1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 3/20 0.65
MAPT P10636 3/20 0.65
ALDH1A1 P00352 2/20 0.65
GAA P10253 2/20 0.65
ALOX5 P09917 1/20 0.65
BACE1 P56817 1/20 0.65
ALOX15 P16050 3/20 0.48
CA2 P00918 2/20 0.48
HDAC1 Q13547 4/20 0.45
HDAC6 Q9UBN7 4/20 0.45
IGF1R P08069 1/20 0.45
CA12 O43570 1/20 0.44
CA1 P00915 1/20 0.44
CA4 P22748 1/20 0.44
CA6 P23280 1/20 0.44
CA5A P35218 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
CA5B Q9Y2D0 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11528973 0.89 ALOX15 (0.54) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL3190378 0.84 ALOX15 (0.58) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL1390986 0.82 ALOX15 (0.52) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL29987473 0.82 ALOX15 (0.52) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL10756643 0.82 KDM4E (0.52) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL3699399 0.81 CNR1 (0.64) KDM4EALOX5BACE1ALOX15CA2
SCHEMBL4617657 0.81 ALOX15 (0.46) KDM4EMAPTALDH1A1GAAALOX5
SCHEMBL517444 0.81 TAAR1 (0.67) KDM4EMAPTALDH1A1GAABACE1
Hydroxytyrosol SCHEMBL44363 0.79 MAPT (1.00) KDM4EMAPTALDH1A1GAAALOX5
Hydroxytyrosol SCHEMBL29414541 0.79 MAPT (1.00) KDM4EMAPTALDH1A1GAAALOX5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-112457171-B Synthetic method of hydroxytyrosol 深圳市迪克曼科技开发有限公司 2021-05-14 CN claimed
CN-112457171-A Synthetic method of hydroxytyrosol 深圳市迪克曼科技开发有限公司 2021-03-09 CN claimed
CN-117326917-B Hydroxytyrosol and high-purity large-scale synthesis method thereof 锦州奥鸿药业有限责任公司 2025-04-25 CN disclosed
CN-116888125-B TYK2 inhibitor and application thereof 上海齐鲁制药研究中心有限公司 2024-04-12 CN disclosed
CN-117326917-A Hydroxytyrosol and high-purity large-scale synthesis method thereof 锦州奥鸿药业有限责任公司 2024-01-02 CN disclosed
CN-116888125-A TYK2 inhibitor and application thereof 上海齐鲁制药研究中心有限公司 2023-10-13 CN disclosed
WO-2022213980-A1 TYK2 INHIBITOR AND USE THEREOF 上海齐鲁制药研究中心有限公司 2022-10-13 WO disclosed
CN-114931519-A Synthesis method of hydroxytyrosol and derivatives thereof and application of hydroxytyrosol and derivatives thereof in cosmetics 上海贤鼎生物科技有限公司 2022-08-23 CN disclosed
CN-112457171-B Synthetic method of hydroxytyrosol 深圳市迪克曼科技开发有限公司 2021-05-14 CN disclosed
CN-112457171-B Synthetic method of hydroxytyrosol 深圳市迪克曼科技开发有限公司 2021-05-14 CN disclosed
CN-112457171-A Synthetic method of hydroxytyrosol 深圳市迪克曼科技开发有限公司 2021-03-09 CN disclosed
US-20040142930-A1 Cyclic compounds MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-07-22 US disclosed
US-20040058930-A1 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same BRISTOL-MYERS SQUIBB COMPANY 2004-03-25 US disclosed
US-20030229089-A1 Cyclic compounds TANABE SEIYAKU CO., LTD. (JP) 2003-12-11 US disclosed
WO-2003084959-A1 THIOPENE-BASED TRICYCLIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS COMPRISING SAME BRISTOL-MYERS SQUIBB COMPANY (US) 2003-10-16 WO disclosed
CN-1440393-A cyclic compound TANABE SEIYAKU CO (JP) 2003-09-03 CN disclosed
EP-1277741-A1 CYCLIC COMPOUNDS TANABE SEIYAKU CO., LTD. (JP) 2003-01-22 EP disclosed
EP-1179025-A1 SUPPORTED CATALYSTS AND OLEFIN POLYMERIZATION PROCESSES UTILIZING SAME Cryovac, Inc. (US) 2002-02-13 EP disclosed
US-6197715-B1 USEFUL IN SLURRY AND GAS PHASE POLYMERIZATION OF OLEFINS CRYOVAC, INC. 2001-03-06 US disclosed
WO-2000056787-A1 SUPPORTED CATALYSTS AND OLEFIN POLYMERIZATION PROCESSES UTILIZING SAME CRYOVAC, INC. (US) 2000-09-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040058930-A1 Thiophene-based tricyclic compounds and pharmaceutical compositions comprising same ABCG2, PFAS, CYP2F1 KDM4E 3793/4885MAPT 2887/4885ALDH1A1 1156/4885
US-20030229089-A1 Cyclic compounds PDE3B, PDE5A, PDE9A KDM4E 999/4885MAPT 4760/4885ALDH1A1 1341/4885
US-20040142930-A1 Cyclic compounds PDE3B, PDE4A, PDE5A KDM4E 732/4885MAPT 4747/4885ALDH1A1 1392/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.